Medscape15h
Should ‘Time in Tight Range’ Be the Primary Diabetes Goal?
ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.
Dexcom COO on 15-day glucose sensor, Type 2 coverage
Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors.
Modern Healthcare9h
FDA warns Dexcom over continuous glucose monitor testing
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
Is Ozempic a game-changer for insulin resistance? What you need to know
SaveHealth explores what the research says about Ozempic's effects on insulin resistance and related conditions.
The Cardiology Advisor15h
Baqsimi Approved for Severe Hypoglycemia Treatment in Younger Patients
The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.